Figure 1.

Management Considerations in ICI-Associated Atherosclerosis

Management strategies for immune checkpoint inhibitors (ICI)–treated patients can include monitoring of atherosclerotic burden pre- and post-ICI therapy with serum and imaging biomarkers, and implementation of tailored interventions. Created with BioRender. CT = computed tomography; CCTA = coronary computer tomography angiography; FDA = Food and Drug Administration; hsCRP = high sensitivity C-reactive protein; IL = interleukin; MCP = monocyte chemoattractant protein; MRI = magnetic resonance imaging; Ox LDL = oxidized low density lipoprotein; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1; sCD = serum cluster differentiation; PET = positron emission tomography; TNF = tumor necrosis factor; VCAM = vascular cell adhesion molecule.